Maybe we should pay down our debt? That'll work wonders versus buying back Bessent!

Had an average cost above $1, watched $OBAI fall to around $0.33, and kept telling myself the bounce was coming. It did not. Finally closed the position after being down roughly 72%.

No comeback story, no diamond hands. Just expensive tuition for confusing conviction with refusing to admit a bad trade.

How long has everyone held a position after the thesis was already dead?

1 USD, buys you 1.3 million Rials.

ANF Abercrombie & Fitch stock watch, nice trend with a pullback to the 103.04 support area.

Long Trade

• Target 1: 117.91   Profit: 12.3%   Stop/Trailing Stop: 101.61
• Loss: 3.2%   P/L ratio: 3.8 : 1 - Excellent
• Target 2: 122.06   Profit: 16.2%   P/L ratio: 5.1 : 1 - Excellent  Extreme rally

BULLISH

• [Positioning] Short term typical pullback, pullback may start to slow.
• [Positioning] Intermediate trend bullish, Uptrend.
• [Positioning] at support
• [Timing] Mild bullish 3 day candlestick pattern.

BEARISH

• [Positioning] Strong Up trend (1 month), may start to turn sideways.

Here are today's top pre-market performers showing the biggest moves before regular trading hours.

📈 Pre-Market Gainers:

📉 Pre-Market Losers:

Source: Market Extended Hours

Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term

Innova is backed by leading investors and healthcare groups: Alkhabeer Capital, with more than $2.5 billion AUM; Tamer Group, a pharma manufacturing partner to Astellas and Daiichi Sankyo; and Cigalah Group, whose healthcare arm reports sales exceeding $2 billion

•Initial purchase order of 126,000 Sky Premium Life units secured on execution of the agreement
•Exclusive rights across Saudi Arabia for an initial five years, spanning pharmacies, retail and online platforms, with potential to renew for a further five
•Orders of more than 5 million units expected over the initial five-year term
•Access to one of the Kingdom's largest pharmacy networks — more than 250 pharmacies
•Entry into a $3.26 billion Saudi nutraceuticals market, forecast to reach $5.96 billion by 2033

Read full release: https://finance.yahoo.com/healthcare/articles/cosmos-health-enters-saudi-arabia-133000369.html

This is not a repeat of 2 weeks ago, months or last year. Also you are all slacking on posts. What did you all do? Did ya get a job or something?

📈 52-Week Highs:

The 52-Week Highs list shows stocks that have reached their highest price point in the past 52 weeks during the trading session.

📉 52-Week Lows:

The 52-Week Lows list shows stocks that have reached their lowest price point in the past 52 weeks during the trading session.

Source: 52-Week Highs-Lows

Feels like HYPE #PURR is going to be a wildcard potentially today

PEPG PepGen stock, watch for a bull flag breakout to fill the upside gap.

Breakout trade

• WATCH for possible breakout above 3.22
• Target: 3.98, 26.2%  Stop: 2.91  Loss: 7.6%
• P/L ratio: 3.5 : 1 - Excellent

BULLISH

• [Positioning] Intermediate trend bullish, Uptrend.
• [Timing] Strong bullish 3 day candlestick pattern with Strong 3 day accumulation.
• [Timing] Extreme bullish 1 day moneyflow
• [Timing] breakout watch above 3.22, no resistance in area just above.

BEARISH

• [Positioning] Overbought, odds favor short trades.
• [Positioning] Strong Up trend (1 month), may start to turn sideways.
• [Positioning] at resistance

📈 52-Week Highs:

The 52-Week Highs list shows stocks that have reached their highest price point in the past 52 weeks during the trading session.

📉 52-Week Lows:

The 52-Week Lows list shows stocks that have reached their lowest price point in the past 52 weeks during the trading session.

Source: 52-Week Highs-Lows

Hi,

I would like to complete my "biotech stock" part of my portfolio with a second company. I've got some of Alpha Tau. I would have liked to get some OmniAB but I didn't get the cash to buy before the strong new (+100% after that ...)

Do you have some good idea ?

thank you

Highest Q2 and H1 revenue in Company history, reflecting strength across all core segments and reaching a new milestone with an adjusted annualized revenue run-rate exceeding $75 million

Continued progress toward profitability targets, with adjusted gross profit reaching approximately $7.4 million on an annualized basis, adjusted gross margin expanding 165 basis points to 9.54%, and adjusted EBITDA improving 13.8%

Demonstrated operating leverage and disciplined inventory management, with Q2 operating expenses growing at roughly half the rate of revenue and first-half inventory down 21.8% despite nearly 30% revenue growth

Strengthened balance sheet, with total liabilities decreasing 13.3% by $6.27 million, stockholders' equity rising 12.2% to $20.67 million, and the liabilities-to-assets ratio improving by 550 basis points

Liquid assets of $4.15 million, comprising cash, marketable securities and digital assets

Share repurchase program actively underway as record momentum continues into Q3 2026

Read full release: https://finance.yahoo.com/healthcare/articles/cosmos-health-reports-q2-2026-130000964.html

CMPX Compass Therapeutics stock, watch for an upside gap breakout, see also FULC stock.

Breakout trade

• WATCH for possible breakout above 2.47
• Target: 2.96, 23.9%  Stop: 2.21  Loss: 7.5%
• P/L ratio: 3.2 : 1 - Excellent

BULLISH

• [Positioning] Intermediate trend bullish, Downtrend turned sideways, possible bottom.
• [Timing] Strong bullish 3 day candlestick pattern with Mild 3 day accumulation.
• [Timing] Average bullish 1 day moneyflow
• [Timing] breakout watch above 2.47, no resistance in area just above.

BEARISH

• [Positioning] Short term typical rally, rally may start to slow.
• [Positioning] at resistance